Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Healthcare Stocks Trade Lower
Wed, 27 Jul 01:30 pm

After witnessing some brisk buying activity in the morning, Indian Indices are trading flat in the post noon trading session. Sectoral indices are trading on a mixed note with stocks from the realty and healthcare sectors bearing the maximum brunt while banking and auto are in the green.

The BSE Sensex is trading lower by 29 points (down 0.1%) and the NSE Nifty is trading flat. The BSE Mid Cap index is trading up by 0.1% while the BSE Small Cap index is trading up by 0.2%. Gold prices, per 10 grams, are trading at Rs 30,831 levels. Silver price, per kilogram, is trading at Rs 46,294 levels. Crude oil is trading at Rs 2,893 per barrel. The rupee is trading at 67.23 to the US$.

As per an article in The Economic Times, Lupin is in discussions with Japan's Astellas and Shionogi to buy the off-patent medicine brands they have separately put on the block.

Reportedly, the deal will aid Lupin widen its offering in the Japanese market. Astellas and Shionogi's drugs that are being divested could draw as much as US$100 million for each company.

Notably, Japanese pharmaceutical market is the second largest after US worth around US$ 110 billion. However, Japanese consumers remain brand focused unlike US which has adopted to generic drugs. Japanese companies are concentrating on selling off-patent drugs and aiming to expand on innovative drugs space.

In one of our premium additions of The 5 Minute Wrap Up, threw interesting insights on how Japanese pharmaceutical industry has seen a flurry of deals (Subscription Required) from global companies.

Moreover, experts have estimated the generic markets to grow by US$ 12-15 billion owing to the Japanese government's efforts to push the generics use to 80% by 2020.

Our Pharma sector analyst, Bhavita Nagrani, is of the opinion that Lupin is one of the largest pharma company and its footprint in Japan could provide a huge growth opportunity. She has recently shared a detailed view on the company and valuations in the latest recommendation report of The India Letter. Click Here to know more. Subscribers can also access Lupin's latest result analysis (subscription required) on our website.

Moving on to the news from cement sector... According to an article in a leading financial daily, Ultratech Cement secured 95,000 tons of coal at a premium of Rs 80 per ton in the auction of coal linkages for cement sector. Acquisition was made from Junadhi mines in Chhattisgarh, the reports stated.

UltraTech Cement said that a formal communication vesting the coal linkages in the company's favor is expected in due course.

Moreover, the company also intends to contribute in the future (Subscription Required) auctions for its plants located strategically near the coal mines.

Recently, Ultratech Cement announced its financial results for the first quarter of the financial year 2016-17. The company has posted a 29% growth in its consolidated net profit at Rs 7.8 billion during the quarter compared to the net profit at Rs 6 billion in the same period last year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Healthcare Stocks Trade Lower". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 21, 2018 (Close)